February 2025 update

The text of the update Zhittya sent, word for word. Pictures, charts and layout are in the PDF. Open the PDF.

February 17, 2025, Monthly Update

Topics: 1. Final data on 1st patient’s 6-month follow-up brain scan: 21% increase in blood flow in substantia nigra area of the brain

1. Started neuropathy Medical Research Study
2. Started respiratory (lung damage) Medical Research Study
3. Why modifying the “Right to Try Law” can save lives and advance innovation in health care and medicine.

#1. Final data on our first patient's 6-month follow-up brain scan: 21% increase in blood flow in substantia nigra area of the brain We believe that insufficient blood flow in the brain, especially in the substantia nigra area of the brain, is the cause of the motor defects seen in Parkinson’s disease patients. It is agreed by most Parkinson’s disease experts that the dopamine producing neurons in that area of the brain produce insufficient dopamine to control movement issues. The unknown question is: Why do these neurons produce less dopamine than is needed? We and others believe the reason for their failure to perform is very simple. If the blood flow to that area is diminished, for whatever reason, those neurons and their supportive cells suffer from undernourishment, less oxygen, and insufficient removal of cellular waste products. The issue of the cause of Parkinson’s disease is not settled among Parkinson’s disease experts; however, we believe the evidence is becoming overwhelming that the cause is vascular dysfunction within the brain.

It is critical to understand the microscopic fragile capillaries of the brain to understand Zhittya’s position. Capillaries in the brain are estimated to be 2 to 5 µm (micrometer is a millionth of meter) in diameter. It is estimated the size of a red blood cell is 6 µm. It does not require a PhD to realize pushing a 6 µm red blood cell through a 4 µm pipe is not easy. This problem is compounded by the fact that brain capillaries are extremely fragile, their walls are one endothelial cell thick. They are so small you cannot see them with the naked eye, and you would need a microscope to see one. This is why no mechanical medical intervention can treat this problem, since nothing exists today to fix that issue. The only way to fix this is the human body's own ability to regenerate.

All of your life, your body has naturally regenerated new blood vessels in your brain. As you grew from a child’s brain to an adult brain, you generated billions of new fresh blood vessels to transport blood to brain cells. When you fell off your bicycle at age 10, hit your head, and you had a small concussion, that concussion ruptured small microscopic capillaries within your brain, which stimulated your body to make FGF-1 to initiate the regeneration process in your brain. Zhittya believes that as we age, there are many assaults on our microscopic capillaries in our brains. No one takes issue with the fact that brain damage can result from blocking blood vessels in the brain or reducing blood flow, like in the brain with a stroke. But instead of one large blockage, brain damage can also result from millions of dysfunctional capillaries in the brain, resulting in reduced blood flow to many areas of the brain.

Zhittya has, as of February 17, 2025, dosed over 200 people in medical research studies who have been diagnosed with Parkinson’s disease. The improvements in the patients’ condition have been impressive. Please read Vika’s patient comments section in any of our Monthly Updates to hear from the patients themselves about their improvements. While common sense can witness their improvements, the question remains, “Why did they improve?”

The Washington University Medical School in St. Louis is one of the most respected medical institutions in the world. One of their areas of expertise is being able to measure blood flow through the substantia nigra region of the brain using “functional MRI”. Remember, the substantia nigra region is very small.

About 25 average-sized substantia nigras could fit into a golf ball. Within that 1/25th of a golf ball, there are about 500,000 dopamine producing neurons. I believe when half of those neurons are starved and therefore underperforming, one develops Parkinson’s disease. I also believe as time passes and the micro- vascularization worsens, so will Parkinson’s disease symptoms worsen.

Zhittya believes that 80% to 90% of brain disorders (excluding cancer) are the results of insufficient blood flow in the brain. We know insufficient blood flow in the heart causes heart disease, so why would common sense not infer that insufficient blood flow in the brain would also not cause brain diseases? We have seen improvements in movement, memory, cognitive abilities, mood and more, when we have introduced FGF-1 into the brain to initiate angiogenesis (the growth of new blood vessels).

We now have (as of February 17, 2025) received our final preliminary report on the first test subject to have his brain scanned (to establish a base blood flow in his substantia nigra area) and then a second scan, 6 months after dosing with FGF-1. We refer to the first patient as “Al” (you have seen him in the Updates) and Washington University refers to him as “Z101”. The final preliminary report states, “‘Al’s’ blood flow in his substantia nigra increased 21% over the baseline of 6 months ago”.

We need to recognize all of this data, while amazingly sophisticated to obtain, is still in its infancy as far as being exact. We believe that some of the computer programs utilized had a very difficult time with the calculations of the data because they have never witnessed an increase in blood flow before in that area of the brain. The programs have been designed to measure the ongoing decline of the blood flow in the substantia nigra, so we have to take this data with the realization it is a work in progress and that the software precision may need a lot of tweaking to make it better. Al (Z101) is scheduled to have another brain scan at 12 months and 18 months’ time from the original scan. I would be very happy if every 6 months for the next two years his brain blood flows increases over the starting base level (4 six-month periods of increased blood flows improvement would be wonderful).

Zhittya has three additional Parkinson’s disease patients, who have had their first brain scan taken and are now being dosed with FGF-1. Seeing Al before the first scan, one knew he had Parkinson’s disease and that it was bad. At six months, he dramatically improved. I hope every 6 months his blood flow improves and I hope at 18 months or 24 months he is close to being back to normal and his Parkinson’s disease is no more! I hope each of our next test subjects have similar results and I hope 5 years from now we have proven FGF-1 introduced into the brain intranasally can reverse all brain disorders including stroke, dementia, Alzheimer’s, epilepsy, autism, PTSD, CTE, traumatic brain injuries and more.

Notice: We will not provide details and copies of our studies, the information is “Proprietary” and has cost us a small fortune and has great value to our advancement and a fair justifiable reward to our investors.

#2. Zhittya has started a Neuropathy Medical Research Study Neuropathy is reported to affect 20 to 30 million Americans. Neuropathy is generally accepted to be caused by insufficient blood flow in the feet (or other areas) leading to nerve pain, due to lack of nourishment and oxygen to the neurons. FGF-1 injected into the heart grew new blood vessels, re-establish blood flow to heart muscle cells and enhanced heart function and reduced cardiac pain.

We believe that FGF-1 introduced into the brain has enhanced blood flow in the brain and re-establish blood flow to suffering brain cells. Vika Montano, our Vice President of Strategic Research, proposed we try to treat neuropathy with FGF-1, presently an untreatable disease.

In mid-January, Vika conducted the first Medical Research Study using FGF-1 injected into the foot to treat neuropathy. A volunteer, who has been suffering from neuropathy, was Vika’s first test subject. The patient had neuropathy in both feet; however, he was dosed only his left foot, thereby creating a semi-controlled study. Here is a picture of his foot with targeted 26 injection sites:

Here is a picture of one of the injections:

From what was witnessed in the heart, we believe it takes 60 to 90 days to grow new blood vessels and we believe another 60 to 90 days for the neurons to regenerate and heal. We will keep you posted!

#3 We Have Started a Respiratory Medical Research Study It is reported that heart disease is the number one cause of death in the world, cancer is the number two cause of death, brain disorders is the third and respiratory disease is reported to be the fourth-largest cause of death. Many people, like myself, suffered from COVID-19. I spent 7 days in an ICU on a ventilator, fighting for my life. Since I was a child, I have struggled with allergies and sometimes asthma. Being awake all night working on breathing is no joy.

Several people have asked me, do I believe FGF-1 could address what is referred to as “long COVID”, as they now have developed breathing issues. I do not know the answer to that question.

Dr. Jacobs prepared a White Paper a few years ago on FGF-1 regenerating lung tissue. I would love to regenerate my air pathways and lungs. In mid-January, I dosed for five days, inhaling FGF-1 into my lungs. Was that the best dosage? I don't know. What I do know is it appears to be safe. I guess it will take 60 to 90 days to see if there is any benefit. The first three weeks I feel fine, and I think my airways and lungs are better, but then again, as you know, I am always an optimist.

We will keep you posted on this. I would be very happy if we discover FGF-1 can help regenerate the airways and lungs. I like the idea of being able to breathe.

#4 Why modifying the “Right to Try Law” can save lives and advance innovation in healthcare and medicine.

We have an estimated 100,000+ readers of our Monthly Update. I hope this time next year it will exceed 200,000 readers, as Zhittya needs to advocate for more medical innovation and the freedom to conduct Medical Research Studies for the benefit of all.

In 1998, I left being an Investment Banker working for high-tech companies after 30 years and started this new journey of bringing FGF-1 to patients, first for the heart, then diabetic foot ulcers, then stroke and now, more. After helping start many computer companies, medical device companies and more over 30 years as an Investment Banker, I wanted something slower. The commercial life of an electronics product is measured in months, not years. You knew the product you released today would be obsolete in 24 months.

This brings us to medical discovery. Over the last 27 years (excluding our FGF-1 product), people have shown me medical discovery after medical discovery that is left on the research shelf because the barrier to reach financial viability (positive cash flow) means obtaining USA FDA clearance to sell the drug to patients, is too difficult a hurdle. According to the London School of Economics, to obtain approval in the United States via the USA FDA takes about 18 years and costs 1 to 2 billion dollars. I remember starting mini-computer companies in 1970 for one million dollars, assembling a product in 6 months, having nice sales after one year and then having to develop a replacement product at 18 months before we sold out the business for a profit at 36 months. If the USA FDA regulated telephones, we would all still have AT\&T land lines with rotary phones paying $1.00 a minute for a call, instead of the smartphones we have today.

I have seen amazing medical breakthroughs which have animal data and, in some cases, excellent human data, and they are going nowhere after 20 years because no one has the 18 years or a billion dollars to bring it to market. Big Pharma does not care about discoveries. They just want to sell what they already have at very high prices.

The Right to Try Law was passed in 2017. It was loved by all, except the bureaucrats at the FDA. Since it was passed, Forbes Magazine reports it has only been used 18 times, less than 3 times a year. A medical doctor came to us, stating that he believed our hypothesis on ALS was correct, that it is a vascular disease caused by head trauma. His sister-in-law was diagnosed with ALS. He wanted to know if we would let him try our medicine on her, and we said “yes”. Not a difficult call, she was dying and had very little time, maybe 2 years. The FDA turned her down 2 times. You see, the Right to Try Law requires a doctor certifying the patient will die within 12 months. An ALS patient may have only two years of hell in front of them, but that is not desperate enough for the Federal Right to Try Law. A person with Stage 4 Parkinson’s disease may have five years of hellish life ahead of them, so they do not qualify. Your bureaucracy!

We have advanced rapidly with our Parkinson’s disease Medical Research Studies because we can obtain modifications in our protocols within weeks and not years.

One dosing modification in our USA FDA-cleared clinical trial for the heart, took 18 months and cost me $5 million dollars; $3 million of that money went to lawyers and consultants.

Nevada has its own “Right to Try Law.” It is almost identical to the Federal law, so it is also worthless to patients and medical innovators, such as Zhittya.

Zhittya believes that Nevada is an economically prosperous state because many years ago, the state decided to legalize gambling, no other state would allow gambling. Las Vegas and Reno have become thriving communities, representing 95% of the state’s population and bringing tens of millions of people to Nevada every year. Nevada decided if people want to gamble (as they have for over 4,000 years) then let them gamble. I believe if Nevada modifies its Right to Try Law, thousands, if not millions, of people would come to Nevada from all over the world to obtain an experimental medical treatment now, rather than wait 18 years for the USA FDA to get around to it. A person with critical leg ischemia does not want their leg amputated, since once that happens their life expectancy is measured in months. Yet they do not qualify under the present Right to Try law. If you have a 98% chance of death in two years, your government says you cannot try to save your life?

I bring this topic up since Zhittya is going to be actively pushing for changes in the Federal and State laws to allow people to try and save their lives and/or lessen their sufferings. Again, I think it is Common Sense.

If Zhittya had not found it could conduct Medical Research Studies in the British Virgin Islands 3 years ago on Parkinson’s disease; we would not have the great data to advance our case and 200 people would still be suffering without hope with a horrible disease, Parkinson’s disease.

Please note: At our April 2, 2025 NevadaBio Annual Dinner we hope to have many important Nevada political figures in attendance. It is my hope that we can introduce to them the economic benefits to Nevada of letting sick people try real medical innovation and advance the humanitarian need for this to happen.

A person with Stage 3 Parkinson’s is told there is no hope, an ALS person is told there is no hope, a glioblastoma patient is told there is no hope, but there is hope if people are free to try. Lastly, an ALS patient may have three years of life after diagnosis. Common sense is that when you have a fire in your kitchen, you put it out ASAP before it spreads to the entire house. Yet, the Right to Try laws today state that the entire house must be in a raging out of control fire, then you can call the fire department for help. What is missing here? Common Sense.

I believe 80% of the biotech discoveries of the 1980s, 1990s, 2000s and 2010s have not advanced because the barrier to medical innovation is so high. I believe by allowing sick people the Right to Try and advance a medical innovation would, for the majority of people waiting for these medical breakthroughs to reach them, change that wait from an 18-year wait into a 5-year wait. Still a long time, however, much better than 18 years. Please keep track of our efforts here. We may need your help.

Vika Montano’s Patients’ Comments Section: Every month, I receive emails and phone calls from our test subjects. Here I have selected a few of their comments so you can read what those who have joined our Medical Research Studies are reporting to us.

#1 From: Taco Date: January 17, 2025 at 1:04:21 AM PST To: Vika Montano \<vika@zhittyamedicine.com> Dear Vika, The newsletter of January 2025 did indeed give a beautiful gift!!

My wife (Tanja) was part of Cohort 15, already 1.5 years ago and we were the first Europeans who travelled to the BVI and are still in contact with this cohort but also a few other cohorts. Tanja has improved a lot in the last year. In summer she climbed the Rainbow mountain in Peru: 5200 m (17000 feet!!) and a week ago no problems at all to walk in the mountains of the Canary Islands. I have to say, the Parkinson is not completely gone, she still needs a small amount of Levadopa but it is reduced from 3-4 to 2 tablets a day.

Tanja is still in contact with the neurologist who took her complaints seriously 2 years ago and promised to prove what she suffered from. It happened to be indeed Parkinson after proof with a DAT scan which showed the malfunction of the substantia nigra. The neurologist is now retired but sometimes they see each other at a horse stable. He is very interested in this new result of the FGF-1 experiment. Perhaps a new (DAT) scan could also prove the improvement in her case too. When we see him, we will ask. His successor is unfortunately of the type you and Dan know very well: completely uninterested in FGF-1 because no FDA result etc.

When more results become available about FGF-1, please, please, publish the results in a scientific journal. Not just the latest results but also the experiments with applying using nasal sprays, observed aspects like the return of smell and taste (I hope you have statistical data about this?).

Two years ago, when reading the website of Zhittya I was not very sure about everything and started reading all scientific publications about FGF-1 (I have easy access to all publications because work at University of Amsterdam). There was very little available, except for some eastern (Japanese or Chinese) experiments with mice which showed the remarkable recovery too. It made me more positive that this could be indeed a possible solution. After a Zoom talk with Sam, I became convinced that this was not a hoax and after the BVI I continued to believe that this is indeed a solution to his horrible disease.

Vika, we didn’t meet in the BVI unfortunately but please pass my congratulations for the super result to Dan and wish him all the best.

Best wishes from the Netherlands

Taco

#2 Hi Vika, Sorry it’s taken awhile to get back to you with my improvements.

My enunciation came back by round three! I still slur a word or two once in a great while, especially when I’m tired. I also have 2 other improvements; first my eyes, they stay open almost all the time now! When I start a dosing cycle, my eyes become more open and alert. My other noticeable changes are my hands and fingers. My hands have become more relaxed now and my stiff fingers aren’t “knotted up”. Now they still get stiff and knotted, but that is by the end of the dosing cycle.

My voice has improved too, mainly in this past week! So, I am hopeful again.

My goal is to be walking by my birthday (mid-July).

Thank you again, it has saved my life.

Much love to you…

#3-Dear Vika, I am feeling much better already since my first treatments in the BVI.

A “fog” has been lifted and my clarity of thought and awareness has improved. I feel more engaged in conversations as my word finding and ability to follow the thread of thought is improving. Overall, I have more physical and creative energy which has allowed me to do more outside the house and enjoy life much more.

Tim summed it up when he told me, “I feel like I am getting my Judy back.”

I am so grateful.

Judy

#4 To: Vika Montano \<vika@zhittyamedicine.com> I am doing very well. I’m traveling about twice a month to Tahoe, New Orleans and Las Vegas. I can walk the airports with no assistance, I work out every day and can keep up with younger women. My mind is sharper and more focused. I’m down to two levadopas a day. I’m encouraged. My voice is stronger. Thank you for your support!

#5-From: Jack Subject: I have been back on my FGF-1 for a month now!

Hey there Ms. Montano I was just going to give you a update on my psp condition. Anyway my balance has improved since I started back on my fgf-1 treatment my alertness has definitely been improving considerably too. I still fall quite a bit but I think it’s because of my neuropathy is why I still fall. Anyway I am making some progress and will continue on the path treatment! Thank you so very much for your help with the condition. J.

#6 Dear Dan and Sweet Vika, This is Kerry, Dan's mom from Cohort 32.

Just saying thanks is not enough after experiencing the life altering week we were privileged to share in the British Virgin Islands. Dan is progressing well! As we left SeaTac airport on the date of our return, he commented that he didn't think he was dragging his foot. After returning to work, he caught sight of his shadow and realized his right arm was swinging freely at his side! His brother and I both recognized his "Mask" was lifting, his humor was quick, and his unique chuckle had returned! The FGF-1 treatments are miraculously effective, but equally so is the emotional and mental support manifested by the Cohort 32 gathering. It was difficult to say goodbye to each family, and to the gracious family you have. In addition, the staff at Maria's are kind and caring and so supportive of your work.

I'm certain Dan and Katie will keep you informed of Dan's progress. As I'm two states away I must also rely on their input. I'm determined to "spread the word" and appreciate the online accessibility of your website. You're in my heart and I'm joyful.

Cross Border Medical Tourism Cross Border Medical Tourism services is for those people who want to be considered for Zhittya’s future clinical trials or its current Medical Research Studies. Cross Border’s focus is to fill all available slots in the Medical Research Studies in the British Virgin Islands and The Bahamas, while we wait for other clinics to come online.

Cross Border is working on filling the available slots for the next BVI Medical Research Studies (intranasal FGF-1 for Parkinson’s disease) on the following dates:

Cohort #34: March 10 – 15, 2025

Cohort #35: April 7 – 13, 2025

Cohort #36: May 2 – 7, 2025

I am showing cohorts further out in time since we are filling up faster and have fewer spots open each month.

Please contact Sam Cross at Cross Border Medical if you wish to be considered for the BVI cohorts or slots in The Bahamas. Sam’s email address is: sam.crossbordermedical@gmail.com.

In addition, if you are interested in participating in the brain scan studies which will take place at Washington University in St. Louis, please let Sam know. There are a finite number of slots for the imaging studies. These studies will look at brain blood flow before and after treatment with FGF-1. There has been no reported pain associated with the MRI scan.

Heart Disease Clinical Trials and Medical Research Studies:

Zhittya is proud to announce that we are actively recruiting and selecting patients suffering from late-stage heart disease. FGF-1 was originally used in USA FDA clinical trials to treat severe coronary artery disease. The treatment was shown to be safe and a potentially efficacious treatment for those suffering from coronary heart disease. Watch this ABC Nightly News’ clip on Zhittya’s drug being used for the heart indication: https://www.youtube.com/watch?v=IPtv_0LWK4k Zhittya is now actively recruiting patients to participate in Zhittya’s Medical Research Studies in The Bahamas, as well as future USA FDA clinical trials. If you are interested in participating in these studies, please reach out to Sergiy Montano, our Vice President of Marketing at: sergiy@zhittyamedicine.com and he will assist you from there.

Upcoming events:

April 2, 2025: NevadaBio Org: Annual Awards Dinner

Nevada’s Premier Biotech Organization — Since 2006

NevadaBio was founded in 2006 to encourage the economic and scientific development of biotechnology in Nevada and has hosted numerous biotech events in Nevada where research scientists, medical doctors, young biotech companies, and political leaders have gathered to support Nevada’s efforts in advancing biotechnology.

Sponsors:

Stavros Anthony, Lt. Governor of the State of Nevada

Shelley Berkley, Mayor of Las Vegas

Thomas Burns, Executive Director of the Governor’s Office of Economic Development John Tsarpalas, Executive Director of Nevada Policy Research Institute Dr. Robert Odell, Owner of the Neuropathy & Pain Centers of Las Vegas John Ensign, DVM & Former U.S Senator Dr. Nabil Sakkab, Chairman of BiOWish Technologies Kevin Prince, Registered Patent Agent, Quick Patents Zhittya Genesis Medicine, Medical Research Studies Management Inc. Roth Capital Cross Border Medical Tourism Inc., Foley Law PC, Benjamin Securities Monterey & Dr. Jeffrey Brookman, John & Marianne Gibson, Jim Marsh Save the Date: April 2, 2025 at 5:30 PM NevadaBio’s 2025 Annual Awards Dinner Durango Hotel and Casino This year’s award recipient is Dr. Jack Jacobs, President of Zhittya Genesis Medicine, Inc., who will give a short presentation on the medical science that allowed the reversal of Parkinson’s disease in over 200 people. The topic of his presentation will be:

Parkinson’s Disease — Reversed by Nevada Biotech Company Nevada — Where Biotech Prospers Join us for an enjoyable and enlightening dinner presentation about a new medicine that has been shown to reverse heart disease, Parkinson’s disease, type- 2 diabetes, dementia, Alzheimer’s disease and more.

Seating for the event is limited to 300 people. For more information, please email John Laub, President NevadaBio at John.NevBio@gmail.com.

I am pleased to announce that our President and Chief Scientific Officer, Dr. Jack Jacobs, will be the recipient of the “Man of the Year Award”. This is for Dr. Jacobs' discoveries and development of FGF-1 to treat major causes of death and suffering in the world today. Dr. Jacobs’ brilliant career and outstanding accomplishments over the last 40 years has earned him the honor, which I believe he well deserves. I believe Dr. Jacobs' presentation will show the medical miracle we have achieved in the brain, heart and more. I believe the information will be exciting to everyone who wants health. I have been informed that important elected officials and the media (TV and press) will be attending to learn more about what Zhittya’s breakthrough medicine is accomplishing. We are anticipating around 300 attendees, and I am told over 200 seats have already been taken. We are bringing some of our Parkinson’s disease patients there to show these elected officials that Parkinson’s disease, stroke, dementia, Alzheimer’s disease, CTE, and diabetes sufferers do not have to be abandoned and mistreated — those diseases can be reversed now! Also, I believe small changes in the wording of the “Right to Try Law” would give access to thousands more people who would be better off sooner. Zhittya will fight for those changes in that law.

For more information, please email John Laub, President of Nevada Bio Organization: john.nevbio@gmail.com I think of this event as “Zhittya’s Coming Out Party”. We are going to show the world what we are doing!

Freedom Fest 2025

June 11 – 14 in Palm Springs, California

Dr. Jacobs and I will both be presenting at the FreedomFest in June, where normally many elected government officials attend. Last year, they had over 2,500 attendees. At the 2023 Freedom Fest, they hosted Robert Kennedy Jr. as a Keynote Speaker, and we were able to chat with him there.

Dr. Jacobs in his section below will discuss nerve damage, or neuropathy.

Numerous diseases result from neuropathy, and we believe our FGF-1 can reverse this condition. I will present my case that changing a few words in the “Right to Try Law” could accelerate medical innovation and lessen the pain and suffering of hundreds of thousands of people now!

Dr. Jack Jacobs

As Dan mentioned above, we believe insufficient blood flow in the substantia nigra area of the brain is the cause of Parkinson’s disease. This results in the dopamine producing neurons in that area of the brain not producing sufficient quantities of dopamine to control movement issues. When the blood flow to that area of the brain is diminished, those neurons suffer from undernourishment, lack of oxygen and insufficient removal of cellular waste products.

To measure blood flow in the substantia nigra region of the brain is challenging! It is not like taking an x-ray of a broken arm. The substantia nigra area is very small, taking up an area of the brain roughly ½ the size of a pea. Obstructions of the microvasculature of the substantia nigra that could fit on the head of a pin can lead to Parkinson’s disease.

Capillaries measure in size from about 5 to 10 microns in diameter (for comparison, a fine strand of human hair has a diameter of 75 microns). Capillaries are so small that red blood cells can only travel through them in single file as shown in the figure below.

Red blood cells passing single file through a capillary.

Now, one can readily imagine that it would not take much narrowing of that capillary above by atherosclerosis or some other insult to disrupt blood flow or blood perfusion, leading to an oxygen-starved or ischemic tissue. FGF-1, by virtue of its ability to stimulate the growth of new blood vessels such as the one above, can restore proper blood perfusion in damaged tissues or organs.

We are just beginning to get some images looking at blood flow in the brains of our Parkinson’s disease patients, before and after treatment with FGF-1. We were very excited to see in our first patient a 21% increase in blood flow in the substantia nigra region of the brain, as shown in the figures below. I want to stress that there are no guarantees that this increase in blood flow will remain that way in this patient or that we will see similar results in other patients that we treat, but we are very gratified with these results.

The pictures below show imaging of blood flow in the brain before and 6 months after treatment with FGF-1. Red areas are areas of low blood flow, yellow shows areas of high blood flow. The areas outlined in white represent the location of the substantia nigra region of the brain.

First Visit, Before Treatment:

Second Visit, After Treatment:

Zooming into the region of the substantia nigra, a significant increase in blood flow is apparent after treatment with FGF-1. As you can see below, the small substantia nigra region has more blood flow (shown in yellow) 6 months after the original dosing, where the original base imaging showed a lack of blood flow (show in red).

First Visit, Before Treatment

Second Visit, After Treatment (21.2% increase in blood flow)

We were very grateful to see these results. Again, one tree does not make a forest, but what we are doing, what no one has done before. I am sure there will be variances between the patients we treat, and it will be great to have perfusion data from 100 patients, so we can have greater confidence in our results, but this is not a bad way to start off!

Conclusion by Dan Montano

This Update is very full. We are advancing on many tasks. I hope we will start the animal testing (3rd one) for the FDA to grant us permission to conduct the human heart trial again, thereby giving us what, I believe, is a treatment for the number one cause of death in the world. We are awaiting one additional event which, I believe, will enhance that project.

We are advancing on brain disorders, including Parkinson’s disease, dementia, stroke, PSP, CTE and more in a cautious and very deliberate way. We are also advancing on the lungs, the legs, the feet and more. I am sure Big Pharma cannot believe all we have done with multi-billions of dollars unmet medical needs, like neuropathy. Vika thinks and says, “Why not try FGF-1 on neuropathy in the feet”.

She says, “If we are correct, 20 to 30 million people in the USA and maybe 600 million around the world will benefit”. A month later, our first patient was dosed in a Medical Research Study on neuropathy. Maybe in 6 months we will know if it is viable. Lungs, well, they're my lungs, and I want to find out if I can fix them. I think I am healthy; however, I know my greatest weakness is my respiratory system and if I can fix it before I have a serious issue, why not, it is my life. After a one-week review and we are clear to go and while I do not know if it will help, I do know at that dosing level it did no harm. We can accelerate medical advancement by being able to try. If a great American football player develops CTE, why must he not be treated until his only relief comes from suicide? Why are 35 American military personnel committing suicide every day from PTSD when I believe taking FGF-1 up the nose (with no pain or skin broken) can return their brains to normal? Why does a neurologist tell the patient there is no hope for them, when there is?

On February 11, 2025, I celebrated 21 years of happiness with Vika. February 11th was also our 23rd wedding anniversary, so I figure she has given me 21 great years of happiness out of the 23 years that we have been married. I believe she has had an excellent 90% performance success record. I did not ask her if I had a 100% performance record over the last 23 years, but for those of you who know me, is it possible I was less than perfect?

Every night when I go to my bed, I talk to God. I have never heard a voice answering my questions or concerns. What I have heard in the silence is clarity in my mind over what is right, what is wrong, and what I must do to prove my life matters. I have had so many disasters in my life, I used to wonder why God let that happen to me. Now, at 76 years of age, I can see why those disasters occur; I was forced to learn a lesson and change a course of action. We at Zhittya have accomplished the impossible, we have done what Big Pharma said could not be done. We are free to try and change the world. Every person around Zhittya knows their life has purpose, and they have been chosen not by me, but by something much bigger. Who would have guessed that an unemployed, overaged bookkeeper, half Mexican, half Irish, born in the slums of East Los Angeles, would lead a band of heroes to be the first people in history to show blood flow in the brain can be enhanced and maybe change the outcome of the lives of hundreds of millions of people. I know my mother would be proud of me. I know my father would ask what took me so long to get it done.

I pray we do not fail you and the millions who need us to succeed!

Bless you all!

Dan Montano, CEO

Zhittya Genesis Medicine

1120 North Town Center Drive, Suite #270,

Las Vegas, Nevada 89144

United States of America zgm.care

[mailto:sam.crossbordermedical@gmail.com](mailto:sam.crossbordermedical@gmail.com)

<https://www.youtube.com/watch?v=IPtv_0LWK4k>

[mailto:sergiy@zhittyamedicine.com](mailto:sergiy@zhittyamedicine.com)

[mailto:John.NevBio@gmail.com](mailto:John.NevBio@gmail.com)

[mailto:john.nevbio@gmail.com](mailto:john.nevbio@gmail.com)

<https://www.zgm.care/>